Warnings without guidance: patient responses to an FDA warning about ezetimibe

Medical Care
William H ShrankDaniel Carpenter

Abstract

In January 2008, the Food and Drug Administration (FDA) communicated concerns about the efficacy of ezetimibe, but did not provide clear clinical guidance, and substantial media attention ensued. We investigated the proportion of patients who discontinued therapy and switched to a clinically appropriate alternative after the FDA communication. Using claims data from a national pharmacy benefits manager, we created a rolling cohort of new users of ezetimibe between January 2006 and August 2008 and created a supply diary for each patient in the year after cohort entry. A patient was identified as nonpersistent if a gap of 90 days was seen in the diary. Using segmented linear regression, we compared rates of nonpersistence before and after the FDA communication and assessed patient-level characteristics associated with discontinuation. Among nonpersistent patients, we determined whether a patient made a clinically appropriate switch in the subsequent 90 days by adding a new cholesterol-lowering medication or by increasing the dose of an existing one. We used a weighted t test to compare the rates of appropriate switching before and after the communication. Among 867,027 new ezetimibe users, 407,006 (46.9%) were nonpersistent in th...Continue Reading

References

Oct 30, 2001·American Journal of Epidemiology·S SchneeweissR J Glynn
Aug 14, 2002·Journal of Clinical Pharmacy and Therapeutics·A K WagnerD Ross-Degnan
Mar 15, 2005·The American Journal of Emergency Medicine·Jeanne L JacobyMichael Heller
Nov 30, 2006·Archives of Internal Medicine·Paaladinesh ThavendiranathanNiteesh K Choudhry
Oct 2, 2007·The Journal of Thoracic and Cardiovascular Surgery·Alexander KulikNiteesh K Choudhry
Jan 9, 2008·Archives of General Psychiatry·Mark OlfsonBenjamin G Druss
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Apr 1, 2008·The New England Journal of Medicine·Jeffrey M DrazenGregory D Curfman
Jun 14, 2008·Journal of Developmental and Behavioral Pediatrics : JDBP·Amy CheungAnthony Levitt
Jan 13, 2010·Archives of Internal Medicine·E Ray DorseyG Caleb Alexander
Aug 18, 2010·Journal of General Internal Medicine·Seema ParikhNiteesh K Choudhry

❮ Previous
Next ❯

Citations

Sep 27, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Keith B HoffmanColin B Erdman
Oct 4, 2016·Current Atherosclerosis Reports·Karen M GoldsteinHayden B Bosworth
Jan 12, 2019·Circulation. Cardiovascular Quality and Outcomes·Ann Marie NavarMichael A Blazing
Jun 4, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jessica T DeFrankOlivia Burrus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Drug Safety
Matilda Florentin, Moses S Elisaf
Transplantation Proceedings
A Guisado RascoA Martínez Martínez
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Tobias R TürkOliver Witzke
© 2021 Meta ULC. All rights reserved